Introduction
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic cardiomyopathy characterized by ventricular arrhythmias and structural abnormalities of the right ventricle (RV) [1, 2] . Pathologically, ARVD/ C is characterized by progressive replacement of right ventricular myocardium with fatty and fibrous tissue [3] . The precise prevalence of ARVD/C is unknown because patients with clinical diagnosis represent only one spectrum of the disease. However, the prevalence of the disease has been estimated to be 1 in 1000 to 1 in 10,000 in the Veneto region of Italy. Cardiovascular diseases account for 2.1 sudden deaths per 100,000 athletes per year, out of which ARVD accounts for 22.4% of deaths in the same region of Italy [4] . Since the first description of the disease by Marcus et al. [1] , there have been considerable advancements in our understanding of ARVD/C. The purpose of this article is to review the current understanding of ARVD/C and its management.
Opinion statement
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic cardiomyopathy characterized by ventricular arrhythmias and structural abnormalities of the right ventricle (RV). The most important aspect in the treatment of ARVD/C is establishing a correct diagnosis based on the International Task Force criteria. In our experience, cardiologists are not aware of these diagnostic criteria for ARVD/C and place too much importance on the results of magnetic resonance imaging of the RV. Patients with ARVD/C generally all have an abnormal 12-lead electrocardiogram, abnormal echocardiogram, and ventricular arrhythmias with a left bundle branch block morphology. If noninvasive testing suggests ARVD, invasive testing with an RV angiogram, RV biopsy, and electrophysiology study are recommended. We encourage patients to participate in the National Institutes of Health-sponsored multicenter clinical trial of ARVD/C (http://www.ARVD.com or http://www.ARVD.org). Once a diagnosis of ARVD/C is established, the main treatment decision involves whether to implant an implantable cardioverter-defibrillator (ICD). ICDs are recommended for patients who have experienced syncope, sudden death, or a sustained ventricular arrhythmia, and also for patients with overt evidence of ARVD, particularly if the electrophysiology study is abnormal or there is a family history of sudden death. We also recommend treatment of patients with ARVD/C with β blockers and angiotensin-converting enzyme inhibitors, and that all patients with ARVD/C be screened for a mutation in the gene for plakophilin-2, because this is present in more than one third of patients with ARVD/C and may be helpful in the management of firstdegree relatives.
CLINICAL PRESENTATION AND NATURAL HISTORY
The clinical characteristics of ARVD/C were first reported by Marcus et al. in 1982 [1] . Patients with ARVD/C most commonly come to clinical attention because of the ventricular arrhythmias. The ventricular arrhythmias, which originate in the diseased RV, may be asymptomatic and detected by routine electrocardiogram (ECG), or they may cause palpitations, syncope, or sudden cardiac death (SCD) [5] . Although ARVD/C is an uncommon cause of SCD, it has been estimated that ARVD/C accounts for approximately 3% to 10% of SCD in individuals under the age of 65 years. Exercise has been identified as a common precipitant of arrhythmias that occur in ARVD/C [4, 6, 7] .
DIAGNOSIS OF ARVD/C
The diagnosis of ARVD is established based on the criteria set by the Task Force of the Working Group of Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology [8] . These criteria are shown in Table 1 . Specific cardiac tests that are recommended in all patients suspected of having ARVD/C include an ECG, a signal-averaged ECG (SAECG), a Holter monitor, and an echocardiogram. When appropriate, more detailed analysis of RV size and function can be provided by cardiac magnetic resonance (CMR) and computed tomography. If the results of the noninvasive tests point toward a diagnosis of ARVD/C, invasive testing (including endomyocardial biopsy, RV angiography, and electrophysiology testing) is recommended to establish the diagnosis and help provide further information to guide treatment recommendations.
ELECTROCARDIOGRAPHIC EVALUATION
ECG abnormalities are detected in up to 90% of patients with ARVC. T-wave inversion (TWI) in leads V1-V3 is a well-established ECG feature of ARVD/C. In the absence of a right bundle branch block, it is considered as a minor diagnostic criterion. The juvenile pattern of TWI (normal variant in children < 12 years of age) is present in 1% to 3% of the healthy population that is 19 to 45 years of age, but is present in 87% of patients with ARVD/C. TWI beyond V1 in a patient in the above age group who has no apparent heart disease but does have ventricular arrhythmias of left bundle branch block morphology should raise the suspicion of ARVD/C [9]. 
